Our wealth of experience and expertise, our understanding of the latest regulatory guidance and industry whitepapers and our commitment to research and development has made Sekisui XenoTech a trusted partner and expert consultant to 39 of the top 40 pharmaceutical companies worldwide, as well as numerous biotech; small, medium and virtual pharma; and other organizations.
Sekisui XenoTech's strong reputation for high quality in vitro drug metabolism studies attracted the attention of Sekisui, who became our parent company in August, 2008. This alignment has allowed us to offer a much wider range of services to accelerate drug development, including the areas of in vivo ADME, Drug Metabolism, Transporters and Drug-Drug Interactions.
As a premier provider of in vitro drug metabolism and drug-drug interaction studies to pharmaceutical companies worldwide, we have unparalleled experience in evaluating drug candidates as substrates, inhibitors and inducers of drug-metabolizing enzymes. Core capabilities include Enzyme Inhibition, Enzyme Induction, Drug Metabolism, Drug Transport and Analytical Services.
Offices in United States: